Neuren Pharmaceuticals Ltd Market Cap ($1.70 Billion)
Market Cap & Net Worth: Neuren Pharmaceuticals Ltd (NEU)
Neuren Pharmaceuticals Ltd market cap. Neuren Pharmaceuticals Ltd (AU:NEU) has a market capitalization of $1.70 Billion (AU$2.40 Billion) as of November 7, 2026. Listed on the AU stock exchange, this Australia-based company holds position #6493 globally and #159 in its home market, demonstrating a 15.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuren Pharmaceuticals Ltd's stock price AU$23.24 by its total outstanding shares 126639526 (126.64 Million). Also see NEU operating cash flow for how efficiently the company converts equity into cash flow.
Neuren Pharmaceuticals Ltd Market Cap History (2015–2026)
Neuren Pharmaceuticals Ltd market cap history from 2015 to 2026. Data shows growth from $206.09 Million to $2.08 Billion (24.95% CAGR). Check NEU stock price and chart for real-time trading data and today's change.
Index Memberships
Neuren Pharmaceuticals Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P/ASX All Australian 200
AXAT
|
$1.95 Trillion | 0.09% | #126 of 200 |
|
S&P/ASX 300
AXKO
|
$2.20 Trillion | 0.08% | #140 of 300 |
|
ASX Small Ordinaries
AXSO
|
$287.79 Billion | 0.59% | #54 of 200 |
Weight: Neuren Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neuren Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neuren Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Neuren Pharmaceuticals Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.25x
Neuren Pharmaceuticals Ltd's market cap is 5.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.89x
Neuren Pharmaceuticals Ltd's market cap is 7.89 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $206.09 Million | $1.67 Million | -$13.40 Million | 123.19x | N/A |
| 2016 | $103.94 Million | $3.15 Million | -$12.01 Million | 33.00x | N/A |
| 2017 | $286.74 Million | $631.00K | $3.29 Million | 454.42x | 87.21x |
| 2018 | $125.45 Million | $13.99 Million | $3.07 Million | 8.97x | 40.82x |
| 2019 | $222.22 Million | $495.00K | -$10.82 Million | 448.93x | N/A |
| 2020 | $115.14 Million | $717.00K | -$9.19 Million | 160.59x | N/A |
| 2021 | $337.81 Million | $3.20 Million | -$7.79 Million | 105.67x | N/A |
| 2022 | $712.36 Million | $14.55 Million | $184.00K | 48.95x | 3871.54x |
| 2023 | $2.24 Billion | $231.93 Million | $157.08 Million | 9.65x | 14.24x |
| 2024 | $1.12 Billion | $213.24 Million | $142.04 Million | 5.25x | 7.89x |
Competitor Companies of NEU by Market Capitalization
Companies near Neuren Pharmaceuticals Ltd in the global market cap rankings as of November 7, 2026. Also see NEU total asset value for a full breakdown of the balance sheet.
Key companies related to Neuren Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Neuren Pharmaceuticals Ltd (2015–2026)
Market capitalization of Neuren Pharmaceuticals Ltd from 2015 to today. Between 2015 and today, Neuren Pharmaceuticals Ltd's market cap moved from $206.09 Million to $ 2.08 Billion, with a yearly change of 24.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$2.08 Billion | +24.88% |
| 2025 | AU$1.67 Billion | +48.88% |
| 2024 | AU$1.12 Billion | -49.94% |
| 2023 | AU$2.24 Billion | +214.09% |
| 2022 | AU$712.36 Million | +110.88% |
| 2021 | AU$337.81 Million | +193.39% |
| 2020 | AU$115.14 Million | -48.19% |
| 2019 | AU$222.22 Million | +77.14% |
| 2018 | AU$125.45 Million | -56.25% |
| 2017 | AU$286.74 Million | +175.86% |
| 2016 | AU$103.94 Million | -49.57% |
| 2015 | AU$206.09 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Neuren Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.70 Billion USD |
| MoneyControl | $1.70 Billion USD |
| MarketWatch | $1.70 Billion USD |
| marketcap.company | $1.70 Billion USD |
| Reuters | $1.70 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more